We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ventas' (VTR) Q4 FFO In Line, Revenues Surpass Estimates
Read MoreHide Full Article
Ventas, Inc. (VTR - Free Report) reported fourth-quarter 2016 normalized funds from operations (“FFO”) of $1.03 per share, in line with the Zacks Consensus Estimate. The bottom-line figure for the prior-year quarter was also $1.03.
The bottom line for full-year 2016 came in at $4.13 per share, in line with the Zacks Consensus Estimate. The full-year 2015 FFO was $3.95 per share.
The company posted revenues of $875.7 million in the fourth quarter, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago tally of $841.3 million.
For full-year 2016, revenues came in at $3.44 billion, up from the 2015 tally of $3.29 billion.
For the fourth quarter, same-store cash net operating income (“NOI”) growth for total portfolio (1,189 assets) was 2.9% on a reported basis. Notably, triple net same-store cash NOI grew 4.5%, the seniors housing operating portfolio same-store NOI grew 1.1% and the medical office building portfolio rose 2.1%.
Notable Portfolio Activity
The company expects to close its $700 million loan commitment to fund Ardent Health Services’ acquisition of LHP Hospital Group late in first-quarter 2017.
In Jan 2017, Ventas sold assets and received final repayment on loans receivable for proceeds of $88 million.
Liquidity
Presently, the company has more than $2 billion available under its revolving credit facility and $286.7 million of cash or cash equivalents in hand.
2017 Outlook
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017.
Further, Ventas expects dispositions of $900 million in 2017. It intends to use the net proceeds to expand the company’s life science and acute care hospital platforms and for debt repayment.
Our Take
Going forward, we believe that Ventas’ adequate size and scale would help it capitalize on opportunities such as increasing healthcare spending, aging population and a rise in insured individuals. Yet, stiff competition and a projected rise in interest rates keep us concerned.
We now look forward to the earnings releases of DDR Corp. , Vornado Realty Trust (VNO - Free Report) and HCP, Inc. (HCP - Free Report) which are expected next week.
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ventas' (VTR) Q4 FFO In Line, Revenues Surpass Estimates
Ventas, Inc. (VTR - Free Report) reported fourth-quarter 2016 normalized funds from operations (“FFO”) of $1.03 per share, in line with the Zacks Consensus Estimate. The bottom-line figure for the prior-year quarter was also $1.03.
The bottom line for full-year 2016 came in at $4.13 per share, in line with the Zacks Consensus Estimate. The full-year 2015 FFO was $3.95 per share.
The company posted revenues of $875.7 million in the fourth quarter, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago tally of $841.3 million.
For full-year 2016, revenues came in at $3.44 billion, up from the 2015 tally of $3.29 billion.
Modest NOI Growth
For the fourth quarter, same-store cash net operating income (“NOI”) growth for total portfolio (1,189 assets) was 2.9% on a reported basis. Notably, triple net same-store cash NOI grew 4.5%, the seniors housing operating portfolio same-store NOI grew 1.1% and the medical office building portfolio rose 2.1%.
Notable Portfolio Activity
The company expects to close its $700 million loan commitment to fund Ardent Health Services’ acquisition of LHP Hospital Group late in first-quarter 2017.
In Jan 2017, Ventas sold assets and received final repayment on loans receivable for proceeds of $88 million.
Liquidity
Presently, the company has more than $2 billion available under its revolving credit facility and $286.7 million of cash or cash equivalents in hand.
2017 Outlook
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017.
Further, Ventas expects dispositions of $900 million in 2017. It intends to use the net proceeds to expand the company’s life science and acute care hospital platforms and for debt repayment.
Our Take
Going forward, we believe that Ventas’ adequate size and scale would help it capitalize on opportunities such as increasing healthcare spending, aging population and a rise in insured individuals. Yet, stiff competition and a projected rise in interest rates keep us concerned.
Currently, Ventas carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ventas, Inc. Price, Consensus and EPS Surprise
Ventas, Inc. Price, Consensus and EPS Surprise | Ventas, Inc. Quote
We now look forward to the earnings releases of DDR Corp. , Vornado Realty Trust (VNO - Free Report) and HCP, Inc. (HCP - Free Report) which are expected next week.
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>